Healthcare providers’ best estimate of how many of their patients would switch to a novel long-acting HIV treatment (n=120), 2019
| Characteristics | Category | N | HCP estimate of what percentage of their patients would actually switch to LAR (regimen Z) | |
| Estimated proportion of patients (unadjusted) | Incidence rate ratio (adjusted) | |||
| Total | 25.7 | |||
| HCP gender | Female (referent) | 37 | 21.6 | 1.00 (referent) |
| Male | 79 | 27.2 | 1.25 (1.16 to 1.36) | |
| Unknown | 4 | * | * | |
| HCP specialty | HIV/AIDS (referent) | 44 | 23.9 | |
| Infectious disease | 67 | 25.3 | 1.02 (0.94 to 1.12) | |
| Other | 9 | 36.4 | 1.47 (1.29 to 1.67) | |
| Years of practice | ≤15 (referent) | 47 | 25.9 | |
| 16–20 | 39 | 25.8 | 1.02 (0.93 to 1.11) | |
| 21–31 | 34 | 25.2 | 0.96 (0.87 to 1.06) | |
| Number of patients | <220 (referent) | 48 | 30.7 | |
| 220–350 | 34 | 23.7 | 0.80 (0.73 to 0.87) | |
| >350 | 38 | 20.9 | 0.75 (0.68 to 0.83) | |
| Rank | Professor/Consultant (referent) | 64 | 23.0 | |
| Associate/Registrar | 56 | 28.7 | 1.30 (1.18 to 1.43) | |
| Practice setting | Teaching/Specialist hospital (referent) | 36 | 27.8 | |
| General hospital | 44 | 26.9 | 0.68 (0.58 to 0.80) | |
| Other | 40 | 22.5 | 0.71 (0.63 to 0.80) | |
| Percentage of patients that are non-European | <20% (referent) | 81 | 27.2 | |
| ≥20% | 39 | 22.4 | 0.80 (0.72 to 0.88) | |
| Proportion of patients that identify as non-heterosexual | <50% (referent) | 80 | 25.9 | |
| ≥50% | 40 | 25.2 | 1.02 (0.93 to 1.11) | |
| Location of HCP practice | Metropolitan (referent) | 69 | 27.3 | |
| Urban (non-metropolitan) | 39 | 22.1 | 0.84 (0.77 to 0.91) | |
| Other/unknown | 12 | 28.2 | 1.24 (1.09 to 1.41) | |
| Country | France (referent) | 30 | 29.6 | |
| Germany | 30 | 30.5 | 0.99 (0.90 to 1.10) | |
| Italy | 30 | 25.1 | 0.85 (0.77 to 0.94) | |
| UK | 30 | 17.6 | 0.58 (0.52 to 0.65) | |
| Percentage of patients with malabsorption | ≤10% (referent) | 89 | 23.5 | |
| >10% | 31 | 31.9 | 1.38 (1.27 to 1.50) | |
| Percentage of patients with dysphagia | ≤10% (referent) | 87 | 24.4 | |
| >10% | 33 | 29.0 | 1.20 (1.11 to 1.31) | |
| Percentage of patients with gastrointestinal condition interfering with oral intake | ≤10% (referent) | 84 | 23.3 | |
| >10% | 36 | 31.1 | 1.24 (1.15 to 1.34) | |
| Percentage of patients with CNS disorder | ≤10% (referent) | 82 | 22.1 | |
| >10% | 38 | 33.3 | 1.60 (1.48 to 1.74) | |
Because of collinearity, each independent variable was analysed separately, adjusting for years of practice, gender and country of residence. Estimates in bold were statistically significant at p < 0.05.
*Estimates suppressed because of small sample size.
CNS, central nervous system; HCP, healthcare provider; LAR, long-acting regimen.